Clinical laboratory

Neuroprotection by Carbenoxolone Against Ischemia Injury Involves PI3K/Akt Pathway.

PMID 26642720


Previous experimental studies have shown some protective effects on brain ischemic injures in vivo and in vitro models. However, cotreatment with carbenoxolone (Cbx) and phosatidylinositol 3-kinase (PI3K) inhibitor LY 294002 to a focal cerebral ischemia and reperfusion rat model has not been studied yet. Here we investigate their protective effects on neural cells and examine the function of PI3K/Akt pathway in this protection. Both flow cytometry and western blot were used quantitatively and qualitatively to determine cell apoptosis. The neural cell apoptosis is related with Cx43, and Bcl-2/Bax and caspase 3 pathways. The percentage of apoptosis cells following transient middle cerebral artery occlusion (MCAO) in mice decrease with the treatment of Cbx. Our data demonstrated that treatment with Cbx reduced cerebral injury in rats exposed to transient focal ischemia and reperfusion (I/R), and this was mediated by the activation of the PI3K/Akt pathways as well as by blocking the caspase 3 apoptosis pathway. LY294002 blocked the increase in phospho-AKT evoked by Cbx and abolished the associated protective effect. Taken together, these findings provide evidence that Cbx protects neurons against ischemia injury and this neuroprotective effect involves the PI3K/Akt pathway.